Apjohn Ventures Fund is a new venture capital firm based in Kalamazoo, Michigan established to invest primarily in early stage life sciences companies across the Midwest. The goal of the Fund is to provide investors with superior financial returns by making equity investments in innovative life sciences companies with sustainable and outstanding growth potential.

We take our name, Apjohn, from the original family name of one of our founders. The use of this family name reflects our desire to inspire life sciences entrepreneurs to build pharmaceutical successes much like Dr. William E. Upjohn did at the turn of the last century.

We welcome you to our web site and invite you to learn more about Apjohn Ventures.
News

12.9.2013

ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting

11.7.2013

ProNAi to Present Phase II Clinical Data at ASH for PNT2258, a BCL2 Targeted Drug

3.19.2013

BioMarin to Advance BMN-701 for Pompe Disease to Next Phase (2/3) of Development

11.9.2012

ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting

5.15.2012

Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study

3.15.2012

Smarticles Extend Their Reach In ProNAi’s DNAi Approach

1.4.2012

CytoPherx Raises $34 Million to Move Into U.S. Clinical Trials

11.9.2011

Svelte Medical Systems Offers All-In-One Drug-Eluting Stent Application

8.17.2010

BioMarin Acquires ZyStor Therapeutics, Inc.

6.28.2010

Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline

10.7.2005
Angiotech Completes Acquisition of Afmedica

 

Apjohn Ventures  :   269-349-8999  :   350 E. Michigan Avenue  :   Suite 500  :   Kalamazoo  :   Michigan  :   49007